Risk stratification in motor area–related glioma surgery based on navigated transcranial magnetic stimulation data

Tizian Rosenstock, Ulrike Grittner, Ph.D., Güliz Acker, M.D., Vera Schwarzer, Nataliia Kulchytska, Peter Vajkoczy, Ph.D., and Thomas Picht, M.D.

OBJECTIVE Navigated transcranial magnetic stimulation (nTMS) is a noninvasive method for preoperatively localizing functional areas in patients with tumors in presumed motor eloquent areas. The aim of this study was to establish an nTMS-based risk stratification model by examining whether the results of nTMS mapping and its neurophysiological data predict postoperative motor outcome in glioma surgery.

METHODS Included in this study were prospectively collected data for 113 patients undergoing bihemispheric nTMS examination prior to surgery for gliomas in presumed motor eloquent locations. Multiple ordinal logistic regression analysis was performed to test for any association between preoperative nTMS-related variables and postoperative motor outcome.

RESULTS A new motor deficit or deterioration due to a preexisting deficit was observed in 20% of cases after 7 days and in 22% after 3 months. In terms of tumor location, no new permanent deficit was observed when the distance between tumor and corticospinal tract was greater than 8 mm and the precentral gyrus was not infiltrated (p = 0.014). New postoperative deficits on Day 7 were associated with a pathological excitability of the motor cortices (interhemispheric resting motor threshold [RMT] ratio < 90% or > 110%, p = 0.031). Interestingly, motor function never improved when the RMT was significantly higher in the tumorous hemisphere than in the healthy hemisphere (RMT ratio > 110%).

CONCLUSIONS The proposed risk stratification model, based on objective functional-anatomical and neurophysiological measures, enables one to counsel patients about the risk of functional deterioration or the potential for recovery.

https://thejns.org/doi/abs/10.3171/2016.4.JNS152896

KEY WORDS navigated transcranial magnetic stimulation; brain tumor surgery; glioma; predictive model; motor outcome; diffusion tensor imaging; oncology; surgical technique

It is widely accepted that extensive resection of malignant gliomas can improve patient survival and quality of life. Yet this goal must be balanced against the risk of surgically induced neurological deficits, especially when planning surgery in presumed motor eloquent areas. Whereas permanent motor deficits clearly affect a patient’s well-being, even transient deficits can have devastating effects, especially in elderly patients, by preventing the timely administration of adjuvant therapy or by causing complications.

Intraoperative neurophysiological monitoring (IOM) such as direct cortical and subcortical stimulation has
been established to increase safety during the resection of rolandic brain tumors. Yet even when IOM is routinely available, preoperative risk assessment is essential to allow for optimal patient counseling and treatment planning. Navigated transcranial magnetic stimulation (nTMS) has been extensively validated as a reliable tool for exactly analyzing the spatial relation between brain tumors and primary motor areas in a noninvasive fashion. It has been shown that preoperatively examining patients with nTMS enables more extensive resections while reducing the rate of functional deficits. In addition to the topographical information offered, the nTMS examination also provides neurophysiological parameters whose clinical relevance has not been elucidated as yet.

The aim of this study was to analyze whether the topographical and neurophysiological measurements provided by nTMS can be used to predict the motor outcome in patients scheduled for surgery of malignant gliomas near motor eloquent areas.

**Methods**

**Ethical Standard**

The study protocol accords with the ethical standards of the Declaration of Helsinki and was approved by the Ethics Commission of the Charité University Hospital. All patients provided written informed consent for medical evaluations and treatments within the scope of the study.

**Patient Sample**

Prospective data collection started in October 2007 and ended in December 2014. Patients presenting with gliomas, judged according to anatomical MRI to 1) compress or infiltrate the motor cortex and/or 2) be closely related to the corticospinal tract (CST), were included in this study to evaluate the possibility of resection by the responsible senior neurosurgeon. Exclusion criteria for an nTMS evaluation were frequent generalized seizures (more than 1 per week) or cranial implants. In each case a detailed neurological examination was performed preoperatively and 7 days and 3 months postoperatively. All findings were saved in a custom-made database. The following biographical and clinical items were documented: age, sex, antiepileptic or antiedematous medication, Karnofsky Performance Scale (KPS), motor status (according to the British Medical Research Council [MRC] grade where 0 means no muscle activation and 5 means normal muscle strength), and duration of symptoms. The Department of Pathology determined tumor histology according to the WHO classification.

**Magnetic Resonance Imaging**

Cerebral MRI with a contrast-enhanced 3D gradient echo sequence, fluid-attenuated inversion recovery (FLAIR) sequence, and diffusion tensor imaging (DTI) sequence was performed using a 1.5- or 3-T MR imaging unit (GE Healthcare) with an 8-channel head coil, as previously described in detail. An interdisciplinary team of neurosurgeons and neuroradiologists interpreted all MR scans. The contrast-enhanced 3D gradient echo sequence was imported into the nTMS system (eXimia, Nexstim Oy) for generating a 3D reconstruction, which allows for controlling the spatial relation between the brain and the stimulation location.

**Navigated TMS**

Both hemispheres were examined using nTMS, as specified previously. In short, TMS relies on the principle of electromagnetic induction. A powerful electrical current is rapidly discharged through a figure-8 TMS coil, generating a brief, cone-shaped magnetic field. This magnetic field penetrates the skull unattenuated and induces an electrical field in the underlying brain. Stimulation of pyramidal cells, their axons, or surrounding interneurons may result in a motor evoked potential (MEP) depending on the stimulation location and intensity. Motor evoked potentials are recorded by the system’s integrated electromyography (EMG) unit using surface electrodes (sampling rate 3 kHz, resolution 0.3 mV; Neuroline 720, Ambu). Depending on the requirements of each case as regards tumor location and individual clinical situation, EMG activity from the following muscles was recorded: abductor pollicis brevis, first dorsal interosseous (FDI), adductor digiti minimi muscles for the upper extremity and the tibialis anterior and abductor hallucis brevis muscles for the lower extremity.

During the nTMS examination, patients were asked to relax and to keep their eyes open. First, the “hot spot” of the FDI muscle was identified by applying TMS in a dense raster and different coil rotations to obtain the best topographic accuracy. Then, the resting motor threshold (RMT), defined as the lowest stimulation intensity sufficient to induce an MEP (≥ 50μV) in at least 5 of 10 stimulations, was determined and reported in volts per meter at the top of the cortex for each hemisphere. Subsequently, peritumoral mapping for the upper (stimulation intensity: 110% RMT) and lower (median stimulation intensity: 130% RMT) extremity was performed. Finally, mapping with high specificity (stimulation intensity: 105% RMT) was performed to specifically outline the primary motor cortex along the precentral gyrus. The MEP-positive stimulation locations from this sequence were used for subsequent surgical planning.

The nTMS examination and planning process are visualized in Fig. 1.

**Surgical Planning**

For surgical planning, the TMS stimuli locations outlining the primary motor cortex were imported into the surgical planning software in the DICOM format (iPlan 2.0, BrainLab). For DTI tracking, the TMS stimulation points were enlarged to a radius of 3 mm to generate a continuous seed point area. To improve tracking robustness, a second seed point was placed into the anterolateral portion of the ipsilateral cerebral peduncle. Afterward, fiber tracking at 75% of the fractional anisotropy threshold (FAT) and minimum fiber length of 110 mm was performed, as described in detail elsewhere. Clearly aberrant tracts were removed, and the minimum distance between the tumor and the CST was measured. Finally, the
tumorous tissue was visualized in red, and the final map consisting of segmented tumor, TMS stimulation points outlining the primary motor cortex, and TMS-based fiber tracts was made available to the surgical team via the hospital’s intranet (Fig. 1).

Surgery

All patients underwent surgery for tumor resection. The surgical strategy was decided based on each patient’s case history, clinical findings, MRI results, functional map provided by TMS mapping, and TMS-based DTI fiber tracking. During surgery, the functional data were made available either on the navigational screen or by projection into the microscopic view. Intraoperative neurophysiological mapping and monitoring were used at the surgeon’s discretion. If applied, a standardized procedure consisting of monopolar anodal trains of 5 square-wave pulses (0.3 msec, 400 Hz) for cortical and subcortical mapping as well as monitoring of motor function was applied, as previously described.10,14 The following signs were regarded as IOM stop criteria: persistent MEP amplitude reduction over 50% and reproducible MEPs at 5 mA during subcortical dissection. Yet, termination of the tumor resection was decided for each individual based on the specific surgical circumstances and IOM phenomena.

Extent of Resection

Nearly all patients (96%) underwent MRI within 48 hours after surgery. Extent of resection was analyzed critically by an independent neuroradiologist and determined by volumetric assessment of the residual tumor volume based on gadolinium-enhanced T1-weighted images or on FLAIR images in low-grade gliomas. To assess residual tumor volume, we divided resection results into 4 groups according to a common and widely used classification system: gross-total resection (GTR; no residual contrast-enhancing tissue on T1-weighted images and no residual hyperintense tissue on FLAIR images of nonenhancing tumors), subtotal resection (STR; residue < 10 cm³), partial resection (PR; residue > 10 cm³), and biopsy.4

Statistical Analysis

Descriptive statistics were used to analyze the patient
TABLE 1. Univariate analyses of patient characteristics at baseline, according to postoperative motor status

<table>
<thead>
<tr>
<th>Variable</th>
<th>MRC Grade at 7 Days Postop</th>
<th>MRC Grade at 3 Mos Postop</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
<td>Mean</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>58 (51%)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>55 (49%)</td>
</tr>
<tr>
<td>Preop motor status</td>
<td>&lt;0.001†</td>
<td></td>
</tr>
<tr>
<td>MRC grade ≤3</td>
<td>12 (11%)</td>
<td>2.5</td>
</tr>
<tr>
<td>MRC grade 4</td>
<td>41 (36%)</td>
<td>4.0</td>
</tr>
<tr>
<td>MRC grade 5</td>
<td>60 (53%)</td>
<td>4.4</td>
</tr>
<tr>
<td>KPS score</td>
<td>≤70%</td>
<td>17 (15%)</td>
</tr>
<tr>
<td></td>
<td>80%</td>
<td>24 (21%)</td>
</tr>
<tr>
<td></td>
<td>90%</td>
<td>44 (39%)</td>
</tr>
<tr>
<td></td>
<td>100%</td>
<td>28 (25%)</td>
</tr>
<tr>
<td>DOS‡</td>
<td>no deficit</td>
<td>58 (53%)</td>
</tr>
<tr>
<td></td>
<td>&lt;4 wks</td>
<td>34 (31%)</td>
</tr>
<tr>
<td></td>
<td>4–12 wks</td>
<td>8 (7%)</td>
</tr>
<tr>
<td></td>
<td>&gt;12 wks</td>
<td>9 (8%)</td>
</tr>
<tr>
<td>Affected hemisphere</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rt</td>
<td>57 (50%)</td>
</tr>
<tr>
<td></td>
<td>Lt</td>
<td>56 (50%)</td>
</tr>
<tr>
<td>nTMS-based tumor</td>
<td></td>
<td>0.010†</td>
</tr>
<tr>
<td>localization§</td>
<td>M1</td>
<td>21 (39%)</td>
</tr>
<tr>
<td></td>
<td>IntCaps</td>
<td>17 (31%)</td>
</tr>
<tr>
<td></td>
<td>M2</td>
<td>6 (11%)</td>
</tr>
<tr>
<td></td>
<td>M0</td>
<td>10 (18%)</td>
</tr>
<tr>
<td>Tumor histology</td>
<td></td>
<td>0.672‖</td>
</tr>
<tr>
<td></td>
<td>LGG</td>
<td>17 (15%)</td>
</tr>
<tr>
<td></td>
<td>HGG</td>
<td>96 (85%)</td>
</tr>
<tr>
<td>RMT ratio</td>
<td>&lt;90%</td>
<td>36 (32%)</td>
</tr>
<tr>
<td></td>
<td>90%–110%</td>
<td>38 (34%)</td>
</tr>
<tr>
<td></td>
<td>&gt;110%</td>
<td>39 (34%)</td>
</tr>
</tbody>
</table>

DOS = duration of motor symptoms; HGG = high-grade glioma; IQR = interquartile range; LGG = low-grade glioma; RMT ratio = ratio of RMT value of affected hemisphere/healthy hemisphere.

* Mann-Whitney U-test.
† Linear trend test (using Monte Carlo simulations for precision).
‡ Four patients at 7 days and 2 patients at 3 months were unable to explain their medical histories appropriately; thus, they were excluded from analysis.
§ Based on the number of patients with DTI: 54 patients at 7 days after surgery and 42 patients at 3 months after surgery.
‖ Fisher’s exact test (using Monte Carlo simulations for precision).

To test the association of different characteristics with a change in motor status, we used general ordinal regression models, which allows deviation from the proportional-odds assumption required in other ordinal regression models (Stata gologit2). Finally, we tested variables with a significant association in the univariate analyses in a multiple general ordinal regression model for testing a change in motor status, we used general ordinal regression models (Stata gologit2).
Results

Patient Sample

One hundred thirteen patients (55 female, 58 male) with a median age of 51 years (range 20–82 years) and a median KPS score of 90% (range 40%–100%) were included in this study; 53 of the patients (47%) had a preoperative motor deficit. Both hemispheres were equally affected by tumor (57 right and 56 left hemisphere). About one-half (60 of 113) of the patients were preoperatively treated with antiepileptic drugs and 15.9% (18 of 113) with steroids.

Patient clinical characteristics and their association with postoperative motor status appear in Table 1. Motor function deteriorated after the operation in 1 (20%) of 5 patients overall and improved in 8% of those with severe paraparesis (MRC grade < 4) and in 11% of those with mild paraparesis (Fig. 2). Among only those cases with preoperative motor deficits, the motor deficit had occurred within 4 weeks prior to the nTMS examination in two-thirds of the patients, whereas the symptoms had already persisted for more than 4 weeks before functional diagnostics were initiated in one-third of the patients. The patients with a shorter case history (< 4 weeks) had a lower risk for worsening motor function (15% vs 40% in patients with a 4- to 12-week case history) and better chances of recovery (23% vs 20% in patients with a 4- to 12-week case history) after 3 months (p = 0.042).

Patients with a higher KPS score preoperatively had better motor function postoperatively (7 days; Spearman’s ρ = 0.318, p = 0.001; 3 months: Spearman’s ρ = 0.274, p = 0.010; Table 1).

There was no significant difference between high- and low-grade gliomas in terms of postoperative change in motor status (7 days: p = 0.487; 3 months: p = 0.449) and extent of resection (STR vs GTR, p = 0.190).
Navigated TMS Mapping

Bihemispheric motor mapping with nTMS was successfully performed in all patients. No adverse events associated with the examination occurred. Two patients (2%) complained about a transient tolerable headache. The maximal navigational error, calculated by the system’s software after coregistration in each case, was always lower than or equal to 2 mm. The mean RMT for the affected hemisphere was 78.3 V/m (SD 32.5, range 35–293 V/m) and for the healthy hemisphere was 74.9 V/m (SD 29.5, range 29–300 V/m). No significant interhemispheric differences could be found with respect to MEP latency (affected hemisphere [in msec]: mean 23.3, SD 1.9, range 19.1–29.9; healthy hemisphere [in msec]: mean 23.3, SD 1.9, range 19.0–30.4; p = 0.891) or MEP amplitude (affected hemisphere [in μV]: median 371, SD 1690, range 73–9544; healthy hemisphere [in μV]: median 403, SD 1387, range 64–6255; p = 0.248; data not shown).

Neurophysiological Measurements: RMT Ratio

Thirty-eight patients (34%) had an RMT ratio (RMT of the affected hemisphere divided by RMT of the healthy hemisphere) between 90% and 110%, whereas 36 patients (32%) had a ratio lower than 90% and 39 patients (35%) had a ratio higher than 110%.

The distribution of the RMT ratio according to the motor outcome after 7 days and after 3 months is visualized in Fig. 3.

Twenty-eight percent of patients with a preoperative motor deficit and an RMT ratio ≤ 110% demonstrated functional improvement at the 3-month follow-up, whereas none of the patients with a preoperative deficit and an RMT ratio > 110% could regain function (Table 2). Developing a new deficit or experiencing a deterioration in an existing deficit was associated with an RMT ratio > 110% (31% after 7 days and 33% after 3 months) versus an RMT ratio < 90% (19% after 7 days and 23% after 3 months) or between 90% and 110% (11% after 7 days and 29% after 3 months; 7 days: p = 0.031; 3 months: p = 0.227; Fig. 3).

We found no significant correlation between the RMT of the tumorous hemisphere and the preoperative motor status (pareisia group [in V/m]: mean 82.6, SD 39.8, range 36–293; no pareisia group [in V/m]: mean 74.5, SD 24.0, range 35–151; p = 0.350).

The MEP latency and MEP amplitude values were not significantly associated with the postoperative motor status or outcome.

Navigated TMS–Based Fiber Tracking and Tumor Localization

Navigated TMS–based fiber tracking was successful in all 54 cases (48%) in which DTI-capable MRI sequences were acquired. The mean FAT value was 0.26 (SD 0.09, range 0.07–0.48).

According to the nTMS mapping and fiber tracking results, the primary motor cortex and/or the CST were infiltrated (M1) in 21 patients (39%), and the tumor was ≤ 8 mm from the CST (IntCaps) in 17 patients (31%). In 16 cases (30%), the tumor was > 8 mm from the CST; in 6 cases (11%) the tumor was directly adjacent to M1 (M2), and in 10 cases (18%) the tumor neither infiltrated nor was directly adjacent to the primary motor cortex (M0). Whereas a critical tumor location (M1 and IntCaps) was responsible for all postoperative motor deteriorations, no functional deterioration due to subcortical injury was observed in any patient with tumors > 8 mm from the CST (Fig. 2C and 2D; 7 days: p = 0.014; 3 months: p = 0.002). Therefore, a distance ≤ 8 mm was used as the limiting value for further statistical regression analysis.

A greater distance was also associated with a better postoperative muscle strength grade (7 days: median MRC Grade 4.0 [≤ 8 mm = M1 and IntCaps] vs 5.0 [> 8 mm = M2 and M0], p = 0.007; 3 months: median MRC 4.0 [≤ 8 mm] vs 4.5 [> 8 mm], p = 0.078).

Moreover, a critical tumor location (M1 vs IntCaps vs M2 vs M0) was associated with a higher rate of STR (56% vs 20% vs 67% vs 0%, respectively) or a lower rate of GTR (44% vs 80% vs 33% vs 100%, respectively; p = 0.004).

Extent of Resection and Functional Outcome

According to postoperative MRI (108 patients [96%]), GTR was achieved in 54 patients (50%). In 36 patients (33%) residual tumor was detected at volumes smaller than 10 cm³ (STR). A PR (residue > 10 cm³) was achieved in 13 cases (12%), and a biopsy was performed in 5 cases (5%).

Patient motor function never changed after a biopsy. Furthermore, we did not observe any improvement in motor status after a patient underwent a PR, and 5 patients in this group (38%) deteriorated postoperatively. However, there was no significant association between extent of tumor resection and postoperative motor status in general. A subgroup analysis of our high-risk cases (see definition below) revealed that just 1 patient (7%) who underwent STR experienced a worsening condition postoperatively, whereas 11 patients (46%) in the GTR group experienced deterioration (7 days: p = 0.024; Table 2).

Multiple Ordinal Logistic Regression

In multiple ordinal logistic regression analyses, the pre-
FIG. 3. Box plots illustrating the distribution of the RMT ratio (quotient of RMT of the affected and healthy hemisphere), according to the motor outcome after 7 days (upper) and after 3 months (lower). Physiologically, the RMT does not show a significant interhemispheric difference in healthy subjects. Box plot shows that most of the patients who could improve had a ratio in the green area (ratio between 90% and 110%). In contrast, cases with postoperative motor deterioration more often had a ratio higher than 110% (or lower than 90%, respectively). Figure is available in color online only.
operative motor status, RMT ratio, and nTMS-based tumor localization remained significantly associated with the postoperative motor change at 7 days after surgery (R² = 0.30; Table 3). A pathological RMT ratio (> 110% and < 90%) was associated with a lower probability of improvement and a higher probability of worsening, as compared with an RMT ratio between 90% and 110%. The same was true for critical tumor localizations.

When analyzing the postoperative motor change after 3 months, the RMT ratio was not significantly associated (R² = 0.19; Table 3). As in the model for the 7-day motor status change, a lower preoperative motor status and safer tumor localizations were associated with a lower probability of worsening.

**Risk Stratification**

Using results of the logistic regression analysis, we classified patients into high- and low-risk groups (for postoperative deterioration of motor function). High-risk criteria were glioma infiltrating the primary motor cortex (M1) and/or a distance ≤ 8 mm between tumor and CST and/or a pathological excitability of the motor cortices (inter-hemispheric RMT ratio < 90% or > 110%). On the other hand, we could assign patients with a noneloquently located tumor (M0, M2, distance to CST > 8 mm) with 2 equally excitable motor cortices into a group of low-risk cases (Table 2). Thus, there were 46 (85%) high-risk cases and 8 (15%) low-risk cases.

Regarding motor outcome, the likelihood of motor improvement was higher in the low-risk group (7 days: 25%; 3 months: 13%) than in the high-risk group (7 days: 4%; 3 months: 9%). None of the patients in the low-risk group and 13 patients (38%) in the high-risk group developed a new permanent deficit (7 days: p = 0.032; 3 months: p = 0.106).

The individual probability for the postoperative motor outcome after 7 days and 3 months can be calculated using the equations in Table 4.

**Discussion**

**Main Study Finding**

Functional-anatomical and neurophysiological measurements derived from presurgical nTMS analysis allowed us, for the first time, to assess the risk of functional deterioration and the potential for functional recovery in Rolandic glioma surgery by using objective data. The most relevant results for presurgically balancing risks and benefits, counseling patients, and planning surgeries are summarized in Table 2.
TABLE 4. Equations for the individual probability for postoperative motor outcome

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Equation</th>
</tr>
</thead>
<tbody>
<tr>
<td>After 7 days for improvement: L = 1.07 - 1.50 *(MRC grade 4) - 1.04 *(MRC grade ≤3) + 1.00 *(RMT ratio &lt;90%) + 2.57 *(RMT ratio &gt;110%) + 2.93 *M1 + 3.12 *IntCaps + 1.55 *M2</td>
<td></td>
</tr>
<tr>
<td>for worsening: L = 4.43 +1.50 *(MRC grade 4) + 1.04 *(MRC grade ≤3) - 1.00 *(RMT ratio &lt;90%) - 2.57 *(RMT ratio &gt;110%) - 2.93 *M1 - 3.12 *IntCaps - 1.55 *M2</td>
<td></td>
</tr>
<tr>
<td>Probability for no change is p = 1 − p(improvement) − p(worsening)</td>
<td></td>
</tr>
<tr>
<td>After 3 mos for improvement: L = 2.10 - 0.33 *(MRC grade 4) - 3.51 *(MRC grade ≤3) + 2.20 *M1 + 2.03 *IntCaps + 0.13 *M2</td>
<td></td>
</tr>
<tr>
<td>for worsening: L = 2.11 + 0.33 *(MRC grade 4) + 3.51 *(MRC grade ≤3) - 2.20 *M1 + 2.03 *IntCaps - 0.13 *M2</td>
<td></td>
</tr>
<tr>
<td>Probability for no change is p = 1 − p(improvement) − p(worsening)</td>
<td></td>
</tr>
</tbody>
</table>

Example, Here, we calculate the risk for motor deterioration in a patient w/ no preop deficit (MRC grade 5) whose tumor infiltrates the motor cortex (M1) and whose interhemispheric RMT ratio is >110%.

L_{1.0} = 4.33 +1.50 *(MRC grade 4) + 1.04 *(MRC grade ≤3) - 1.00 *(RMT ratio <90%) - 2.57 *(RMT ratio >110%) - 2.93 *M1 - 3.12 *IntCaps - 1.55 *M2 = -1.17

p(worsening) = 1/(1 + exp[−1.17]) = 76%

L_{1.0} = 2.11 + 0.33 *(MRC grade 4) + 3.51 *(MRC grade ≤3) - 2.20 *M1 - 2.03 *IntCaps - 0.13 *M2 = -0.09

p(worsening) = 1/(1 + exp[−0.09]) = 52%

exp(L) = e^L, where e is Euler’s number.

* The value in front of the asterisk should be applied when the condition behind the asterisk is fulfilled. In the example, the portion of the equation with a line through it signifies the portion that does not apply.

nTMS mapping in patients with brain tumor in a presumed motor eloquent location leads to a higher rate of GTR and longer progression-free survival while at the same time reducing the rate of permanent deficits. In addition, it has been shown that the insertion of nTMS data into CST tractography increases the accuracy and specificity of fiber tracking in a user-independent manner compared with those achieved with conventional fiber tracking based on anatomical landmarks. To further improve the clinical utility of nTMS, we propose a model of nTMS-based risk stratification. The model allows one to identify cases at high risk for incurring a new postoperative motor deficit by using objective measures. In addition, the model predicts which cases with preexisting deficits have a chance of recovery. The nTMS analysis facilitates preoperative risk-benefit balancing and patient counseling as well as the consequent decision making.

Risk Stratification Based on nTMS

On the cortical level, tumorous invasion of the primary motor cortex—that is, nTMS-proven function within the border zone of the cortical aspect of the glioma—is a risk factor for postoperative functional deficit. Subcortically, nTMS-based fiber tracking has recently been introduced as a reliable method for visualizing the CST. In the current study, no new postoperative motor deficit was observed when the minimum distance between tumor and CST was > 8 mm. If there is no other risk factor, such cases can be categorized into the low-risk group and GTR should be the surgical goal. None of the patients in the low-risk group had a deteriorated motor status postoperatively.

Careful surgical planning and treatment are indicated in high-risk cases, in which the minimum distance between tumor and CST is ≤ 8 mm. On one hand, patients with direct tumor infiltration of the CST had the highest rate of motor worsening. On the other hand, we also observed cases with postoperative improvement in motor function, which probably reflects a more conservative surgical strategy in this group resulting in (transient) functional improvement through tumor debulking. In this context, the high rate of GTR-associated (46%) deficits in our subgroup analysis of high-risk cases is a very important finding. The fact that just 1 patient with STR experienced deterioration may reinforce the necessity of carefully balancing the additional benefit of GTR against the significant risk of inducing a permanent deficit. The use of IOM must be seen as mandatory in high-risk cases.

With respect to cortical excitability, equally excitable hemispheres (RMT ratio 90%–110%), as occur in healthy subjects, were associated with a better outcome and can therefore be handled as low-risk cases. In contrast, patients with a pathological RMT ratio should be treated as high-risk cases. Although the RMT ratio was only included in the model for motor outcome after 7 days, the results also indicated a correlation with long-term deficits. However, a patient’s motor status on Day 7 is a relevant factor since it affects the timing of further treatment, for example, adjuvant therapy. At this moment there is no proven explanation for this correlation. Perez and Cohen, among others, reported a significant imbalance in interhemispheric inhibition in patients with paresis after stroke. More specifically, a strong inhibition of the affected hemisphere by the healthy one leads to increased motor deficits and reduced capacity for functional rehabilitation. Our results fit this observation since the rate of motor deterioration was especially high in patients with an RMT ratio > 110%, that is, with impaired excitability of the tumor hemisphere. Moreover, patients with impaired excitability of the tumorous hemisphere and a preexisting motor deficit never showed improvement in motor function postoperatively.

In addition to the nTMS-based factors, the preoperative motor status and the duration of motor symptoms are also significantly associated with the relative motor outcome. Regarding clinical status, patients with a preoperative deficit and a shorter case history had a better chance of improving their motor status.

Our multiple ordinal logistic regression analysis allowed us to classify tumors in motor-associated areas into high-risk and low-risk cases. This nTMS-based risk stratification enables objective and individualized risk-benefit balancing and facilitates patient counseling and surgical planning.
Study Limitations
The proposed nTMS-based risk stratification model is based on statistically highly significant data. Yet, we cannot exclude the possibility that our results were influenced by the specific decision-making processes and treatment algorithms of our department. This study is the first to disclose a predictive utility of nTMS. Next, the presented results must be validated by external data.

Conclusions
The nTMS-based risk stratification can be routinely applied when treating patients with a brain tumor in presumed motor eloquent regions. In high-risk cases the use of IOM is strongly advised, whereas IOM in low-risk cases is not obligatory. In addition, the patient can now be better informed about individual chances and risks of tumor resection.

References
28. Siiusänen L, Julkunen P, Niskanen E, Hukkanen T, Mervaala


**Disclosures**
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

**Author Contributions**
Conception and design: Rosenstock, Acker, Picht. Acquisition of data: Rosenstock, Schwarzer, Kulchytska. Analysis and interpretation of data: Rosenstock, Picht. Drafting the article: Rosenstock. Critically revising the article: Rosenstock, Grittner, Acker, Vajkoczy, Picht. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Rosenstock. Statistical analysis: Rosenstock, Grittner. Administrative/technical/material support: Rosenstock, Schwarzer, Kulchytska, Vajkoczy, Picht. Study supervision: Vajkoczy, Picht.

**Correspondence**
Tizian Rosenstock, Department of Neurosurgery, Charité University Medicine, Augustenburger Platz 1, Berlin 13353, Germany. email: tizian.rosenstock@charite.de.